Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Liminal BioSciences Inc. LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed... see more

Add To Watchlist

Recent & Breaking News (NDAQ:LMNL)

ProMetic expands clinical application of plasminogen to include the treament of diabetic wounds

Canada NewsWire November 11, 2015

ProMetic's PBI-4050 data on renal fibrosis and pancreatic function featured at the American Society of Nephrology's annual meeting

Canada NewsWire November 9, 2015

Prometic to report its third quarter 2015 financial results and hold conference call / webcast

Canada NewsWire November 6, 2015

ProMetic's plasminogen drug successfully used to treat plasminogen deficient infant in critical condition

Canada NewsWire November 4, 2015

ProMetic Announces the Appointment of Its New Chief Financial Officer

Marketwired November 2, 2015

ProMetic's PBI-4050 Cleared to Commence Clinical Trial in Patients With Type 2 Diabetes and Multi-Organ Fibrosis in Europe

Marketwired October 29, 2015

ProMetic's IVIG IND Cleared by FDA

Marketwired October 26, 2015

ProMetic's PBI-4050 Granted Orphan Drug Designation for the Treatment of Idiopathic Pulmonary Fibrosis in Europe

Marketwired October 13, 2015

ProMetic Reports Successful PBI-4050 Pre-IND Meeting with the US FDA for Idiopathic Pulmonary Fibrosis ("IPF")

Marketwired October 1, 2015

ProMetic's PBI-4050's Positive Safety Review Triggers Expansion of Phase II Clinical Trial in Metabolic Syndrome Patients

Marketwired August 27, 2015

ProMetic Reports its Second Quarter 2015 Highlights and Financial Results

Marketwired August 13, 2015

ProMetic Closes the Acquisition of Emergent BioSolutions' Plasma Collection Center in Winnipeg, Canada

Marketwired August 13, 2015

ProMetic Successfully Completes First Dosing in Plasminogen Deficient Patients

Marketwired August 10, 2015

ProMetic to Report its Second Quarter 2015 Financial Results and Hold Conference Call / Webcast

Marketwired August 7, 2015

ProMetic to Report its Second Quarter 2015 Financial Results and Hold Conference Call / Webcast

Marketwired August 7, 2015

European Commission Grants Orphan Drug Designation to ProMetic's Plasma-Derived Plasminogen Drug

Marketwired August 4, 2015

European Commission Grants Orphan Drug Designation to ProMetic's Plasma-Derived Plasminogen Drug

Marketwired August 4, 2015

ProMetic Provides Update Regarding GENERIUM's Large-Scale Plasma Purification Facility

Marketwired June 16, 2015

ProMetic's PBI-4050 Anti-Fibrotic Effect Confirmed on Human Kidney Cells

Marketwired June 1, 2015

ProMetic to Acquire Emergent BioSolutions' Plasma Collection Center in Winnipeg, Canada

Marketwired May 28, 2015